Dendreon’s Provenge - 40% Increased Survival - “New Treatment Paradigm” for Cancer!
March 3rd, 2010 | Posted by Mike KearneyDendreon announced updated results today from its pivotal Phase 3 IMPACT trial for late stage prostate cancer. The results were even better than we expected. According to Dendreon, the study “demonstrated that PROVENGE increased three-year survival by 40 percent compared to placebo.”
This is truly awesome and in line with what we always believed about the potential of Provenge and Immunotherapy. Dr. Phillip Kantoff, the Director of the Lank Center for Genitourinary Oncology, Chief of the Division of Solid Tumor Oncology, and Chief Clinical Research Officer at Dana-Farber Cancer Institute, Professor of Medicine at Harvard Medical School, and principal investigator of the IMPACT study, said it best:
“The results from the IMPACT study corroborate earlier studies with sipuleucel-T in demonstrating an improvement in overall survival for men with metastatic castration resistant prostate cancer.”
This is why CareToLive, represented by our attorney, Kerry M. Donahue, fought so long and so hard to keep Provenge in the limelight after the FDA delayed approval for almost 3 years to date.
The earlier studies which were reviewed by an FDA Advisory Committee back in March 2007 demonstrated survival, the FDA gold standard for approval of cancer treatments, especially for terminal patients who had no other options, yet we are still awaiting approval.
Dr. Kantoff reminded us that we are seeing medical history:
“This is the first therapeutic vaccine to demonstrate a survival benefit in cancer.”
This goes way beyond prostate cancer because Dendreon is going to use similar treatments to try to tackle other cancers, such as breast, colon , ovarian cancer, etc.
Although safety was never a concern in prior trials, rumors abounded, and today, Dr. Kantoff, in the press release, tames that concern while reiterating the medical history we are about to experience:
“Furthermore, the results of this study validate cancer immunotherapy as an entirely new treatment paradigm that can provide patients with a clinically meaningful survival benefit coupled with a well-tolerated safety profile.”
CareToLive is thrilled to proudly broadcast this great news.
The three-year survival by 40% compared to placebo is record breaking. Now we need the FDA to enable the men in dire need to get Provenge ASAP!
Popularity: 17%
Tags: Adam Feuerstein, cancer, CareToLive, Dendreon, FDA, Howard Scher, Immunotherapy, Jim Cramer, Kerry M. Donahue, maha hussain, Matthew Herper, Mike Huckman, Prostate Cancer, provenge, Richard Pazdur, SEC, Wall Street
March 15th, 2010 at 4:14 pm
[…] Dendreon's Provenge – 40% Increased Survival – “Nеw Treatment … […]
March 22nd, 2010 at 1:21 pm
This has been a long time a coming. We’ve been following DNDN for 10 years. We were part of the orginal Chicago 13 as well as walked in Maryland to protest the unjustice of the FDA. Melody along with her husband are the true troopers and believers. Arnie in Chicago, hats off to you. So many people I would like to say “Thank you for your time, effort & courage”. Best of wishes to all, bless you & again, Thank you, Fred & Berlinda Waldenfels
April 27th, 2010 at 1:05 pm
I hope it gets approved may 1,2010 but after reading and reading and reading I feel that provenge will not get approved by the fda because to the provenge is like space,the human brain and deep ocean.The fda need the world’s greatest scientists on the planet to approve provenge and with fat cat molasses slugs the fda has it is way easier to say no and walk across the street than to say YES on provenge and fly to the moon with a fda slingshot
May 3rd, 2010 at 3:21 am
[…] Dendreon's Provenge – 40% Increased Survival – “Nеw Treatment … […]